Murine oncogenicity and pharmacokinetics studies of 9-cis-UAB30, an RXR agonist, for breast cancer chemoprevention

• Published in: International journal of toxicology Vol. 29; no. 2; p. 157
• Main Authors: Kapetanovic, Izet M, Horn, Thomas L, Johnson, William D, Cwik, Michael J, Detrisac, Carol J, McCormick, David L
• Format: Journal Article
• Language: English
• Published: United States 01.03.2010
• Subjects: Animals; Area Under Curve; Breast Neoplasms - prevention & control; Carcinogenicity Tests; Dose-Response Relationship, Drug; Fatty Acids, Unsaturated - blood; Fatty Acids, Unsaturated - pharmacokinetics; Fatty Acids, Unsaturated - toxicity; Female; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Naphthalenes - blood; Naphthalenes - pharmacokinetics; Naphthalenes - toxicity; Retinoid X Receptors - agonists; Tumor Suppressor Protein p53 - genetics
• ISSN: 1092-874X
• DOI: 10.1177/1091581809360070

The synthetic retinoic acid analog, 9-cis-UAB30 [(2E,4E,6Z,8E)-8-(3',4'-dihydro-1'(2'H)-naphthalen-1'-ylidene)-3,7-dimethyl-2,4,6-octatrienoic acid], is a specific ligand for the retinoid X receptor. Murine oncogenicity and pharmacokinetics studies were performed as part of the preclinical development of 9-cis-UAB30 for breast cancer chemoprevention. In the oncogenicity study, TSG-p53((+/-)) (p53 knockout) mice (25 per sex per group) received daily gavage exposure to 9-cis-UAB30 doses of 0 (control), 30, 100, or 300 mg/kg/d for 6 months. Positive controls received p-cresidine (400 mg/kg/d) for 6 months. 9-cis-UAB30 had no biologically significant effects on survival, body weight, body weight gain, clinical signs, hematology, or clinical chemistry but induced dose-related hepatomegaly in both sexes and decreased thymus weights in high-dose females. Gross and microscopic pathology provided no evidence of 9-cis-UAB30 toxicity or oncogenicity; by contrast, p-cresidine induced urinary bladder neoplasms in more than 60% of male and female mice. It was concluded that 9-cis-UAB30 is not oncogenic in p53((+/-)) mice. In the pharmacokinetics study, C57BL/6 mice received daily gavage exposure to 9-cis-UAB30 (100 or 300 mg/kg/d) for 1 or 7 days. Pharmacokinetic parameters were similar after 1 and 7 days of dosing. Dose-related peak plasma levels of 9-cis-UAB30 were seen between 0.25 and 3 hours; volume of distribution was comparable at both dose levels. Increases in area under the curve were less than proportional to dose and were associated with an increased rate of apparent clearance and decreased elimination half-life. These results suggest decreased absorption and/or possible induction of clearance mechanisms. Enzyme induction may underlie the hepatomegaly seen in mice treated with 9-cis-UAB30 for 6 months in the oncogenicity study.